Releuko® (filgrastim-ayow) is an FDA-approved biosimilar to Neupogen® (filgrastim).
Filgrastim is a man-made form of granulocyte colony-stimulating factor (G-CSF), a substance naturally produced by the body that stimulates the growth of neutrophils (nu-tro-fils). Neutrophils are a type of white blood cell important in the body’s fight against infection. When
Chemotherapy, an autoimmune disease or an infection may lower your neutrophil counts, resulting in a condition called neutropenia. Neutropenia can cause swelling and repeated infections. Releuko is used to treat this condition.
How to Use
Releuko injections can be given by a healthcare professional via intravenous (IV) infusion or under your skin (subcutaneous injection). Your healthcare provider may decide subcutaneous injections can be given at home by you or your caregiver. If Releuko is given at home, see the detailed “Instructions for Use” that comes with your Releuko prescription for information on how to prepare and inject a dose of the medication.
Who should NOT take Releuko?
Patients who have had a serious allergic reaction to human G-CSFs such as filgrastim or pegfilgrastim products should NOT take Releuko.
PATHways provides you with a straight-forward range of resources and services designed to easily map your personal path toward more accessible medication. Learn what is available to you and how to keep things moving along your individual treatment path.